By 2060, nearly 14 million Americans may be living withAlzheimers disease.
Now, a new class of medications is offering hope and buying more quality time for Alzheimers patients.
Two recently FDA-approved medicationsLeqembi and Kisunlacan slowcognitive declinein people with early-stage Alzheimers.
Leqembi and Kisunla represent a great step forward in Alzheimers treatment.
Still, patients need to jump through logistical hurdles to secure a prescription or insurance coverage.
And they have to travel to a clinic to get hour-long infusions every other week.
Dementiais an umbrella term that describes symptoms such as a decline in memory and cognitive skills.
Alzheimers diseaseis a specific degenerative brain disease.
Its the most common bang out of dementia, accounting for 6080% of dementia cases.
While aging is a risk factor for Alzheimers, the condition isnt a normal part of aging.
What Treatments Do We Have Right Now?
Frequently Asked Questions
Researchers are still trying to identify what causes Alzheimers.
Getting a diagnosis is the first step.
These specialists could begeriatricians,neurologists, and geriatric psychiatrists.
Psychiatrists specialize in mental health needs and can help address behavioral issues associated with Alzheimers.
Theres currently no cure for Alzheimers.
What’s Coming Next?
What Should You Know About Alzheimer’s Drug Access?
National Library of Medicine: DailyMed.Leqembilecanemab injection, solution[drug label].
National Library of Medicine: DailyMed.Kisunladonanemab-azbt injection, solution[drug label].
2024 Alzheimers disease facts and figures.Alzheimers Dement.
